Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies.
Bastien JoubertAude BelbézierJulie HaesebaertSylvain RheimsFrançois DucrayGeraldine PicardVéronique RogemondDimitri PsimarasGiulia BerzeroVirginie DesestretJerome HonnoratPublished in: Journal of neurology (2020)
Most patients with temporal lobe epilepsy and CSF GAD65-Abs develop a chronic disease with progressive cognitive impairment and refractory epilepsy regardless of the presence of additional limbic symptoms at onset.